del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia

C. Cameron Yin, Lynne V. Abruzzo, Xiaoyan Qiu, Effrosyni Apostolidou, Jorge E. Cortes, L. Jeffrey Medeiros, Gary Lu

Research output: Contribution to journalArticle

Abstract

The del(15q) chromosomal abnormality is known to occur in acute leukemias, but has rarely been described in chronic myelogenous leukemia (CML). Described here are five cases of CML associated with del(15q): four men and one woman. Bone marrow aspirate smears showed increased blasts in all cases at the time of del(15q) detection, in accelerated phase in two cases and myeloid blast phase in three. Conventional cytogenetic analysis showed t(9;22) and del(15q), as well as other inconsistent clonal abnormalities. All patients received imatinib mesylate; four received additional chemotherapy, and two had allogeneic stem cell transplantation (ASCT). Of the three patients who did not receive ASCT, one died, one was in persistent blast phase, and one was in clinical remission with molecular evidence of residual disease at 16, 6, and 34 months, respectively, after identification of the del(15q). Of the two patients who had ASCT, one died and one was in clinical remission with molecular evidence of disease at 15 and 64 months, respectively, after identification of the del(15q). These findings indicate that del(15q) is a recurrent cytogenetic abnormality that may be seen at initial presentation of advanced disease or may emerge during disease progression. Del(15q) appears to be associated with a poor prognosis in CML.

Original languageEnglish (US)
Pages (from-to)18-23
Number of pages6
JournalCancer Genetics and Cytogenetics
Volume192
Issue number1
DOIs
StatePublished - Jul 1 2009
Externally publishedYes

Fingerprint

Clonal Evolution
Stem Cell Transplantation
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chromosome Aberrations
Blast Crisis
Cytogenetic Analysis
Disease Progression
Leukemia
Bone Marrow
Drug Therapy

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia. / Yin, C. Cameron; Abruzzo, Lynne V.; Qiu, Xiaoyan; Apostolidou, Effrosyni; Cortes, Jorge E.; Medeiros, L. Jeffrey; Lu, Gary.

In: Cancer Genetics and Cytogenetics, Vol. 192, No. 1, 01.07.2009, p. 18-23.

Research output: Contribution to journalArticle

Yin, C. Cameron ; Abruzzo, Lynne V. ; Qiu, Xiaoyan ; Apostolidou, Effrosyni ; Cortes, Jorge E. ; Medeiros, L. Jeffrey ; Lu, Gary. / del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia. In: Cancer Genetics and Cytogenetics. 2009 ; Vol. 192, No. 1. pp. 18-23.
@article{1c02bec1e1e847cb88ea118061e3478d,
title = "del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia",
abstract = "The del(15q) chromosomal abnormality is known to occur in acute leukemias, but has rarely been described in chronic myelogenous leukemia (CML). Described here are five cases of CML associated with del(15q): four men and one woman. Bone marrow aspirate smears showed increased blasts in all cases at the time of del(15q) detection, in accelerated phase in two cases and myeloid blast phase in three. Conventional cytogenetic analysis showed t(9;22) and del(15q), as well as other inconsistent clonal abnormalities. All patients received imatinib mesylate; four received additional chemotherapy, and two had allogeneic stem cell transplantation (ASCT). Of the three patients who did not receive ASCT, one died, one was in persistent blast phase, and one was in clinical remission with molecular evidence of residual disease at 16, 6, and 34 months, respectively, after identification of the del(15q). Of the two patients who had ASCT, one died and one was in clinical remission with molecular evidence of disease at 15 and 64 months, respectively, after identification of the del(15q). These findings indicate that del(15q) is a recurrent cytogenetic abnormality that may be seen at initial presentation of advanced disease or may emerge during disease progression. Del(15q) appears to be associated with a poor prognosis in CML.",
author = "Yin, {C. Cameron} and Abruzzo, {Lynne V.} and Xiaoyan Qiu and Effrosyni Apostolidou and Cortes, {Jorge E.} and Medeiros, {L. Jeffrey} and Gary Lu",
year = "2009",
month = "7",
day = "1",
doi = "10.1016/j.cancergencyto.2009.02.017",
language = "English (US)",
volume = "192",
pages = "18--23",
journal = "Cancer Genetics and Cytogenetics",
issn = "0165-4608",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia

AU - Yin, C. Cameron

AU - Abruzzo, Lynne V.

AU - Qiu, Xiaoyan

AU - Apostolidou, Effrosyni

AU - Cortes, Jorge E.

AU - Medeiros, L. Jeffrey

AU - Lu, Gary

PY - 2009/7/1

Y1 - 2009/7/1

N2 - The del(15q) chromosomal abnormality is known to occur in acute leukemias, but has rarely been described in chronic myelogenous leukemia (CML). Described here are five cases of CML associated with del(15q): four men and one woman. Bone marrow aspirate smears showed increased blasts in all cases at the time of del(15q) detection, in accelerated phase in two cases and myeloid blast phase in three. Conventional cytogenetic analysis showed t(9;22) and del(15q), as well as other inconsistent clonal abnormalities. All patients received imatinib mesylate; four received additional chemotherapy, and two had allogeneic stem cell transplantation (ASCT). Of the three patients who did not receive ASCT, one died, one was in persistent blast phase, and one was in clinical remission with molecular evidence of residual disease at 16, 6, and 34 months, respectively, after identification of the del(15q). Of the two patients who had ASCT, one died and one was in clinical remission with molecular evidence of disease at 15 and 64 months, respectively, after identification of the del(15q). These findings indicate that del(15q) is a recurrent cytogenetic abnormality that may be seen at initial presentation of advanced disease or may emerge during disease progression. Del(15q) appears to be associated with a poor prognosis in CML.

AB - The del(15q) chromosomal abnormality is known to occur in acute leukemias, but has rarely been described in chronic myelogenous leukemia (CML). Described here are five cases of CML associated with del(15q): four men and one woman. Bone marrow aspirate smears showed increased blasts in all cases at the time of del(15q) detection, in accelerated phase in two cases and myeloid blast phase in three. Conventional cytogenetic analysis showed t(9;22) and del(15q), as well as other inconsistent clonal abnormalities. All patients received imatinib mesylate; four received additional chemotherapy, and two had allogeneic stem cell transplantation (ASCT). Of the three patients who did not receive ASCT, one died, one was in persistent blast phase, and one was in clinical remission with molecular evidence of residual disease at 16, 6, and 34 months, respectively, after identification of the del(15q). Of the two patients who had ASCT, one died and one was in clinical remission with molecular evidence of disease at 15 and 64 months, respectively, after identification of the del(15q). These findings indicate that del(15q) is a recurrent cytogenetic abnormality that may be seen at initial presentation of advanced disease or may emerge during disease progression. Del(15q) appears to be associated with a poor prognosis in CML.

UR - http://www.scopus.com/inward/record.url?scp=65749090396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65749090396&partnerID=8YFLogxK

U2 - 10.1016/j.cancergencyto.2009.02.017

DO - 10.1016/j.cancergencyto.2009.02.017

M3 - Article

C2 - 19480932

AN - SCOPUS:65749090396

VL - 192

SP - 18

EP - 23

JO - Cancer Genetics and Cytogenetics

JF - Cancer Genetics and Cytogenetics

SN - 0165-4608

IS - 1

ER -